Page 84 - Read Online

Page 6 of 7 Byrne et al. Metab Target Organ Damage 2024;4:10 https://dx.doi.org/10.20517/mtod.2024.06

6. Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated
meta-analysis. Gut 2022;71:156-62. DOI
7. Mantovani A, Petracca G, Csermely A, et al. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-
analysis of about 11 million individuals. Gut 2022;Online ahead of print:gutjnl-2022-327672. DOI PubMed
8. Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a
meta-analysis of observational cohort studies. Gut 2022;71:778-88. DOI
9. Byrne CD. Banting memorial lecture 2022: 'Type 2 diabetes and nonalcoholic fatty liver disease: Partners in crime'. Diabet Med
2022;39:e14912. DOI PubMed PMC
10. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607. DOI PubMed
11. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia,
and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94. DOI PubMed
12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of
the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in
adults (Adult Treatment Panel III). JAMA 2001;285:2486-97. DOI PubMed
13. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged
men. JAMA 2002;288:2709-16. DOI
14. Onat A, Ceyhan K, Başar O, Erer B, Toprak S, Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with
low cholesterol levels--a prospective and cross-sectional evaluation. Atherosclerosis 2002;165:285-92. DOI PubMed
15. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart
disease and diabetes in the West of Scotland coronary prevention study. Circulation 2003;108:414-9. DOI
16. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide
definition. Lancet 2005;366:1059-62. DOI PubMed
17. Grundy SM, Cleeman JI, Daniels SR, et al; American Heart Association; National Heart; Lung; and Blood Institute. Diagnosis and
management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement.
Circulation 2005;112:2735-52. DOI
18. Guzder RN, Gatling W, Mullee MA, Byrne CD. Impact of metabolic syndrome criteria on cardiovascular disease risk in people with
newly diagnosed type 2 diabetes. Diabetologia 2006;49:49-55. DOI PubMed
19. Alberti KG, Eckel RH, Grundy SM, et al; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational
Heart; Lung; and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society;
International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the international
diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association;
world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation
2009;120:1640-5. DOI
20. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart
disease risk. Circulation 1990;82:495-506. DOI PubMed
21. Targher G, Corey KE, Byrne CD. NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment.
Diabetes Metab 2021;47:101215. DOI PubMed
22. Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA
Cardiol 2019;4:1287-95. DOI PubMed PMC
23. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international
expert consensus statement. J Hepatol 2020;73:202-9. DOI PubMed
24. Lazarus JV, Newsome PN, Francque SM, Kanwal F, Terrault NA, Rinella ME. Reply: a multi-society delphi consensus statement on
new fatty liver disease nomenclature. Hepatology 2024;79:E93-4. DOI PubMed
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and
beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9. DOI PubMed
26. Geloneze B, Repetto EM, Geloneze SR, Tambascia MA, Ermetice MN. The threshold value for insulin resistance (HOMA-IR) in an
admixtured population IR in the Brazilian Metabolic Syndrome Study. Diabetes Res Clin Pract 2006;72:219-20. DOI
27. Moura FA, Carvalho LS, Cintra RM, et al. Validation of surrogate indexes of insulin sensitivity in acute phase of myocardial infarction
based on euglycemic-hyperinsulinemic clamp. Am J Physiol Endocrinol Metab 2014;306:E399-403. DOI
28. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the
assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care
2000;23:57-63. DOI
29. Stern SE, Williams K, Ferrannini E, DeFronzo RA, Bogardus C, Stern MP. Identification of individuals with insulin resistance using
routine clinical measurements. Diabetes 2005;54:333-9. DOI PubMed
30. Trépo E, Valenti L. Update on NAFLD genetics: From new variants to the clinic. J Hepatol 2020;72:1196-209. DOI
31. Sung KC, Cha SC, Sung JW, So MS, Byrne CD. Metabolically healthy obese subjects are at risk of fatty liver but not of pre-clinical
atherosclerosis. Nutr Metab Cardiovasc Dis 2014;24:256-62. DOI
32. Chang Y, Jung HS, Cho J, et al. Metabolically healthy obesity and the development of nonalcoholic fatty liver disease. Am J
Gastroenterol 2016;111:1133-40. DOI